Valemetostat

Generic Name: Valemetostat

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄ClN_₃O_₄

CAS Number: 1809336-39-7

Unique Ingredient Identifier: 60RD0234VE

Clinical Trials

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Phase 1

Recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Malignant Solid Neoplasm
Metastatic Prostate Carcinoma
Metastatic Urothelial Carcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
Aggressive Variant Prostate Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8

Interventions: Biological: Ipilimumab
Drug: Valemetostat

First Posted Date: 2020-05-14

Last Posted Date: 2025-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT04388852

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: DS-3201b

First Posted Date: 2020-02-19

Last Posted Date: 2021-02-25

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 28

Registration Number: NCT04276662

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Phase 2

Completed

Conditions: Adult T-cell Leukemia/Lymphoma

Interventions: Drug: Valemetostat Tosylate

First Posted Date: 2019-09-25

Last Posted Date: 2025-02-10

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 25

Registration Number: NCT04102150

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya-shi, Aichi, Japan
🇯🇵
Local Incorporated Administrative Agency Sasebo City General Hospital, Sasebo-shi, Nagasaki, Japan
🇯🇵
Osaka International Cancer Institute, Osaka-shi, Osaka, Japan

and more 21 locations

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Phase 1

Recruiting

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: CC-99282
Drug: Rituximab
Drug: Obinutuzumab
Drug: Tafasitamab
Drug: Valemetostat

First Posted Date: 2019-04-29

Last Posted Date: 2025-02-19

Lead Sponsor: Celgene

Target Recruit Count: 438

Registration Number: NCT03930953

Locations: 🇺🇸
Local Institution - 114, Los Angeles, California, United States
🇩🇰
Rigshospitalet University Hospital, Copenhagen, Denmark
🇩🇰
Local Institution - 603, Vejle, Denmark

and more 87 locations

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: DS-3201b
Drug: irinotecan

First Posted Date: 2019-03-19

Last Posted Date: 2024-10-10

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT03879798

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Commack, Commack, New York, United States

and more 4 locations

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute
Leukemia, Lymphocytic, Acute

Interventions: Drug: DS-3201b

First Posted Date: 2017-04-12

Last Posted Date: 2024-01-31

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 28

Registration Number: NCT03110354

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

DS-3201b in Participants With Lymphomas

Phase 1

Active, not recruiting

Conditions: Lymphoma, Malignant
Non-hodgkin Lymphoma

Interventions: Drug: DS-3201b

First Posted Date: 2016-04-08

Last Posted Date: 2025-02-07

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT02732275

Locations: 🇺🇸
The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, Ohio, United States
🇺🇸
City of Hope National Medical center, Duarte, California, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 17 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy